A Phase II Trial of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in Combination with Bevacizumab and Docetaxel in Patients (pts) with Checkpoint Inhibitor (CPI)-experienced Advanced Non-small Cell Lung Cancer (NSCLC)
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Cadonilimab (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jan 2025 New trial record